Drugs / ODSH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01161641 | Jul 2010 → Feb 2012 | protein-losing enteropathy | Jazz Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODSH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01161641 ↗ |
| Action | Restore | “ODSH has been studied in the rodent model of PLE an has shown improvement of PLE in this model due to restoration of heparan sulfate and Syndecan 1” NCT01161641 ↗ |
| Route | Intravenous | “4-day continuous intravenous infusion” NCT01161641 ↗ |